Liang Junzhi, Na Xinni, Meng Lingbo, He Lixia, Shu Ting, Fang Yuanyuan, Zhang Bowen, Zhao Zhongyu, Guo Cuishan, Li Tingting, Na Zhijing, Li Da, Xiao Xue
Center of Reproductive Medicine Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang China.
Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang China.
MedComm (2020). 2025 Jul 1;6(7):e70245. doi: 10.1002/mco2.70245. eCollection 2025 Jul.
Ten-eleven translocation (TET) family proteins are Fe(II)- and α-ketoglutarate-dependent dioxygenases, comprising three family members: TET1, TET2, and TET3. These enzymes drive DNA demethylation by sequentially oxidizing 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine. Through these reactions, TET proteins remodel the epigenetic landscape and interact with transcription factors and RNA polymerase II to regulate gene expression, cell lineage specification, and embryonic development. Mutations and dysregulation of have been associated with the pathogenesis of various diseases, including the nervous system, immune system, and metabolic diseases, as well as cancers. Therapeutic modulation of TETs may be an effective strategy for the treatment of these diseases. Here, we provide a comprehensive overview of the mechanisms by which TET proteins mediate DNA demethylation and detail their biological functions. Additionally, we highlight recent advances in understanding the molecular mechanisms linking dysregulation to disease pathogenesis and explore their potential as therapeutic targets. This review supplements the current understanding of the critical role of epigenetic regulation in disease pathogenesis and further facilitates the rational design of targeted therapeutic agents for diseases associated with mutations and dysregulation of .
十一易位(TET)家族蛋白是依赖于Fe(II)和α-酮戊二酸的双加氧酶,由三个家族成员组成:TET1、TET2和TET3。这些酶通过将5-甲基胞嘧啶依次氧化为5-羟甲基胞嘧啶、5-甲酰基胞嘧啶和5-羧基胞嘧啶来驱动DNA去甲基化。通过这些反应,TET蛋白重塑表观遗传景观,并与转录因子和RNA聚合酶II相互作用以调节基因表达、细胞谱系特化和胚胎发育。TET的突变和失调与包括神经系统、免疫系统和代谢疾病以及癌症在内的各种疾病的发病机制有关。对TETs进行治疗性调节可能是治疗这些疾病的有效策略。在这里,我们全面概述了TET蛋白介导DNA去甲基化的机制,并详细阐述了它们的生物学功能。此外,我们强调了在理解将TET失调与疾病发病机制联系起来的分子机制方面的最新进展,并探讨了它们作为治疗靶点的潜力。这篇综述补充了目前对表观遗传调控在疾病发病机制中关键作用的理解,并进一步促进了针对与TET突变和失调相关疾病的靶向治疗药物的合理设计。